A skincare startup got bought for $190 million—then shut down. Here's what entrepreneurs can learn from the rise and fall of ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Hims & Hers Health. If we consider the specifics of each trade, it is accurate to state that 40% of the investors opened ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

ProShares UltraPro Short QQQ, Hims & Hers Health, and Teleflex are the three Mid Cap stocks to watch today, according to MarketBeat’s stock screener tool. Mid cap stocks are shares of companies with ...

Learn more about whether Alignment Healthcare, Inc. or Hims & Hers Health, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Hims & Hers Health, Inc. or LifeStance Health Group, Inc. is a better investment based on AAII's A+ ...

The latest trend in treating hair loss may sound familiar — essentially, it's a repurposed drug first popularized in the ...

Cube will underpin many of the AI tools we will develop in the years to come, including highly complex scene-generation tools ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) shares shot up 2.1% during trading on Wednesday after Bank of America raised their price target on the stock from $21.00 to $22.00. Bank of ...

While swiping left and right have become synonymous with dating culture among younger generations, a 2025 Hims study found ...